Dr. Julia White on Determining Risk in Patients With Breast Cancer
Julia White, MD, professor of Radiation Oncology, Ohio State University, discusses the pros and cons of multi-gene assays when trying to determine the risk of local recurrence in patients with breast cancer.
Julia White, MD, professor of Radiation Oncology, Ohio State University, discusses the pros and cons of multi-gene assays when trying to determine the risk of local recurrence in patients with breast cancer. White says in most cases, these assays have already been performed by this point in the treatment sequencing due to oncologists determining if chemotherapy would be the right choice for their hormone-sensitive patients.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
